Furthermore, the relationship between Hippo pathway alterations and major drivers of ccRCC development (such as VHL, SETD2, and BAP2 mutations as well as HIF1 and HIF2α activation) is not currently clear. Here, VHL is linked to nonpapillary renal cell carcinoma.